Achieve, which develops Cytisinicline – a plant-based alkaloid with a high binding affinity to nicotinic acetylcholine receptor – for smoking cessation, said an abstract containing data from the Phase 2b trial dubbed ORCA-1 has been accepted for presentation at the SRNT-E Annual Conference to be held in Oslo, Sept. 12-14.
ORCA-1 is Achieve's first ORCA – Ongoing Research of Cytisinicline for Addiction – program that aims at evaluating the safety and efficacy of the pipeline candidate for smoking cessation, and potentially other addiction indications.
Top-line results from the ORCA-1 study which enrolled 254 smokers at eight centers across the U.S., announced in June showed a 74% to 80% median reduction in the number of cigarettes smoked over a 25-day treatment period compared to 62% for placebo.
The results however did not excite investors, as they pushed the shares down by about 25% June 11.
Achieve said the abstract "A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2b Trial of Cytisinicline in Adult Smokers" and the oral presentation will include updated cytisinicline data from the recently completed ORCA-1 trial.
Achieve traded around $2.42 at time of publication.
The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy
What's Pushing Nano-Cap Biotech DiaMedica's Shares Higher?
See more from Benzinga
- The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics
- The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.